Global Alzheimer's Drugs Market 2014-2018

Global Alzheimer's Drugs Market 2014-2018 is a new market research publication announced by Reportstack. Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.

The analysts forecast the Global Alzheimer’s Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018. This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

The report Global Alzheimer’s Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer’s Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas

• EMEA       


Key Vendors

• Eisai Co., Ltd.

• Forest Laboratories Inc.

• Janssen Pharmaceuticals Inc.

• Novartis AG

Other Prominent Vendors

• Adamas Pharmaceuticals Inc.

• Archer Pharmaceuticals Inc.

• Eli Lilly and Co.

• F. Hoffmann-La Roche Ltd.

• FORUM Pharmaceuticals Inc.

• H. Lundbeck A/S

• Merck & Co., Inc.

• MorphoSys AG

• Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc.

• Takeda Pharmaceutical Co., Ltd.

• TauRx Pharmaceuticals Ltd.

• Zinfandel Pharmaceuticals Inc.

Key Market Driver

• Increasing Aging Population

• For a full, detailed list, view our report

Key Market Challenge

• Poor Diagnosis of Alzheimer’s Disease

• For a full, detailed list, view our report

Key Market Trend

• Increasing Incidence, Prevalence, and Mortality of Alzheimer’s Disease

• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

To view the table of contents and know more details please visit Global Alzheimer's Drugs Market 2014-2018.